Published in J Biol Chem on April 12, 2011
ADP-ribose polymers localized on Ctcf-Parp1-Dnmt1 complex prevent methylation of Ctcf target sites. Biochem J (2012) 1.14
Poly(ADP-ribosyl)ation acts in the DNA demethylation of mouse primordial germ cells also with DNA damage-independent roles. PLoS One (2012) 0.95
MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function. Antioxid Redox Signal (2014) 0.86
Poly(ADP-ribosyl)ation is involved in the epigenetic control of TET1 gene transcription. Oncotarget (2014) 0.83
Poly(ADP-ribose) polymerase 1 promotes transcriptional repression of integrated retroviruses. J Virol (2012) 0.81
Alpha-tocopheryl succinate inhibits autophagic survival of prostate cancer cells induced by vitamin K3 and ascorbate to trigger cell death. PLoS One (2012) 0.81
Altered protease-activated receptor-1 expression and signaling in a malignant pleural mesothelioma cell line, NCI-H28, with homozygous deletion of the β-catenin gene. PLoS One (2014) 0.77
Thrombomodulin expression regulates tumorigenesis in bladder cancer. BMC Cancer (2014) 0.76
Chromatin modifications and their function. Cell (2007) 55.98
Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev (2001) 9.54
Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev (2000) 9.36
Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem (2006) 8.66
The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell (2010) 5.06
Malignant mesothelioma. Lancet (2005) 3.93
Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet (2004) 3.69
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest (1995) 3.21
The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem (1989) 3.14
Venous thromboembolism and cancer: risks and outcomes. Circulation (2003) 2.68
Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest (1983) 2.36
Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer (2010) 1.93
Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol (1985) 1.92
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med (1982) 1.75
Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia (2005) 1.63
CCCTC-binding factor activates PARP-1 affecting DNA methylation machinery. J Biol Chem (2008) 1.62
Thrombomodulin. J Thromb Haemost (2003) 1.60
Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J (2008) 1.54
Wall tension is a potent negative regulator of in vivo thrombomodulin expression. Circ Res (2003) 1.49
Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol (2008) 1.43
Identification of silencing of nine genes in human gastric cancers. Cancer Res (2002) 1.37
Modulation of DNMT1 activity by ADP-ribose polymers. Oncogene (2005) 1.37
Parp1 localizes within the Dnmt1 promoter and protects its unmethylated state by its enzymatic activity. PLoS One (2009) 1.27
The unmethylated state of CpG islands in mouse fibroblasts depends on the poly(ADP-ribosyl)ation process. J Biol Chem (1998) 1.13
Reduced levels of poly(ADP-ribosyl)ation result in chromatin compaction and hypermethylation as shown by cell-by-cell computer-assisted quantitative analysis. FASEB J (1999) 0.98
Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer. Mol Carcinog (2010) 0.96
Cancer and venous thromboembolism: an overview. Haematologica (1999) 0.96
Cellular localization of thrombomodulin in human epithelium and squamous malignancies. Am J Pathol (1995) 0.92
Rate of thromboembolic events in mesothelioma. Ann Thorac Surg (2008) 0.89
Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients. Cancer Lett (2000) 0.87
Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Exp Cell Res (1998) 0.87
Mesothelioma and internal carotid artery occlusion: acute ischemic stroke and efficacy of emergency carotid thrombectomy. Ann Vasc Surg (2009) 0.86
Chromatin architecture and functions: the role(s) of poly(ADP-RIBOSE) polymerase and poly(ADPribosyl)ation of nuclear proteins. Biochem Cell Biol (2005) 0.85
Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology (1995) 0.84
Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol (2009) 0.82
Silencing of the thrombomodulin gene in human malignant melanoma. Melanoma Res (2005) 0.81
Expression of Thrombomodulin in the epithelium of the urinary bladder: a possible source of urinary thrombomodulin. Anticancer Res (1999) 0.76
The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med (2010) 1.84
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol (2012) 1.59
The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr (2002) 1.57
Rotating-shift nurses after a day off: peripheral clock gene expression, urinary melatonin, and serum 17-β-estradiol levels. Scand J Work Environ Health (2014) 1.50
HLA-G and pregnancy adverse outcomes. Med Hypotheses (2011) 1.47
Aging of cardiac myocytes in culture: oxidative stress, lipofuscin accumulation, and mitochondrial turnover. Ann N Y Acad Sci (2004) 1.17
Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II. J Biol Chem (2010) 1.16
FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene (2004) 1.14
Mitochondrial recycling and aging of cardiac myocytes: the role of autophagocytosis. Exp Gerontol (2003) 1.13
Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med (2009) 1.12
Vitamin E analogs, a novel group of "mitocans," as anticancer agents: the importance of being redox-silent. Mol Pharmacol (2007) 1.11
Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin Cancer Res (2009) 1.09
Mitochondria as targets for cancer therapy. Mol Nutr Food Res (2009) 1.08
Mitochondrially targeted anti-cancer agents. Mitochondrion (2010) 1.08
Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clin Cancer Res (2002) 1.07
Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem (2012) 1.06
Anticancer drugs targeting the mitochondrial electron transport chain. Antioxid Redox Signal (2011) 1.04
Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res (2007) 1.04
Mitochondrial complex II, a novel target for anti-cancer agents. Biochim Biophys Acta (2012) 1.03
Relationship of job satisfaction, psychological distress and stress-related biological parameters among healthy nurses: a longitudinal study. J Occup Health (2009) 1.02
Mitochondria play a central role in apoptosis induced by alpha-tocopheryl succinate, an agent with antineoplastic activity: comparison with receptor-mediated pro-apoptotic signaling. Biochemistry (2003) 1.02
Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One (2011) 1.01
alpha-Lipoic acid supplementation inhibits oxidative damage, accelerating chronic wound healing in patients undergoing hyperbaric oxygen therapy. Biochem Biophys Res Commun (2005) 0.99
Vitamin E analogues as anticancer agents: lessons from studies with alpha-tocopheryl succinate. Mol Nutr Food Res (2006) 0.98
Rotating shift-work as an independent risk factor for overweight Italian workers: a cross-sectional study. PLoS One (2013) 0.97
CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP. Biochem Biophys Res Commun (2008) 0.95
Alpha-tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress. J Biol Chem (2005) 0.93
Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a FoxO1-dependent manner. Cancer Res (2011) 0.92
A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression. Cancer Res (2007) 0.92
Vitamin E analogues: a new class of inducers of apoptosis with selective anti-cancer effects. Curr Cancer Drug Targets (2004) 0.91
Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis (2011) 0.91
Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties. Biochem Pharmacol (2003) 0.91
Reactive oxygen species are generated by the respiratory complex II--evidence for lack of contribution of the reverse electron flow in complex I. FEBS J (2013) 0.91
Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Lett (2006) 0.90
Mitocans: mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents. Recent Pat Anticancer Drug Discov (2006) 0.89
The involvement of inflammatory cytokines in the pathogenesis of recurrent miscarriage. Cytokine (2012) 0.89
Mitochondrial targeting of α-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy. Free Radic Biol Med (2011) 0.88
Plasma copper/zinc ratio: an inflammatory/nutritional biomarker as predictor of all-cause mortality in elderly population. Biogerontology (2009) 0.88
Influence of shift-work on selected immune variables in nurses. Ind Health (2011) 0.88
Targeting the mitochondrial electron transport chain complexes for the induction of apoptosis and cancer treatment. Curr Pharm Biotechnol (2013) 0.87
RNA-mediated gene silencing of nicotinamide N-methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells. PLoS One (2013) 0.87
Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev (2008) 0.87
Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat Res (2008) 0.87
MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function. Antioxid Redox Signal (2014) 0.86
Decreased apoptotic response of inclusion-cell disease fibroblasts: a consequence of lysosomal enzyme missorting? Exp Cell Res (2002) 0.86
Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochem Biophys Res Commun (2005) 0.86
Assessment of cardiovascular risk in shift healthcare workers. Eur J Cardiovasc Prev Rehabil (2008) 0.86
alpha-Tocopheryl succinate-induced apoptosis in human gastric cancer cells is modulated by ERK1/2 and c-Jun N-terminal kinase in a biphasic manner. Cancer Lett (2006) 0.85
MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system. Hum Mutat (2008) 0.85
Circadian gene expression and extremely low-frequency magnetic fields: an in vitro study. Bioelectromagnetics (2015) 0.84
Plasticity of neuroendocrine-thymus interactions during ontogeny and ageing: role of zinc and arginine. Ageing Res Rev (2006) 0.84
Alpha-tocopheryl succinate selectively induces apoptosis in neuroblastoma cells: potential therapy of malignancies of the nervous system? J Neurochem (2005) 0.83
Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol (2009) 0.82
Dissociation of apoptosis induction and CD36 upregulation by enzymatically modified low-density lipoprotein in monocytic cells. Biochem Biophys Res Commun (2002) 0.82
A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a future drug against a fatal neoplastic disease? Int J Cancer (2004) 0.82
Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs. Arch Biochem Biophys (2004) 0.82
α-Tocopheryloxyacetic acid is superior to α-tocopheryl succinate in suppressing HER2-high breast carcinomas due to its higher stability. Int J Cancer (2012) 0.82
Role of thioredoxin-1 in apoptosis induction by alpha-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells. FEBS Lett (2006) 0.82
Mitochondrially targeted α-tocopheryl succinate is antiangiogenic: potential benefit against tumor angiogenesis but caution against wound healing. Antioxid Redox Signal (2011) 0.82
Mitochondrially targeted vitamin E succinate modulates expression of mitochondrial DNA transcripts and mitochondrial biogenesis. Antioxid Redox Signal (2015) 0.82
Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. Cancers (Basel) (2010) 0.82
Bid integrates intrinsic and extrinsic signaling in apoptosis induced by alpha-tocopheryl succinate in human gastric carcinoma cells. Cancer Lett (2009) 0.82
Lymphocyte DNA damage precedes DNA repair or cell death after orthopaedic surgery under general anaesthesia. Mutagenesis (2003) 0.81
Alpha-tocopheryl succinate inhibits autophagic survival of prostate cancer cells induced by vitamin K3 and ascorbate to trigger cell death. PLoS One (2012) 0.81
Vitamin E analogues as mitochondria-targeting compounds: from the bench to the bedside? Mol Nutr Food Res (2009) 0.81
Variability of biological effects of silicas: different degrees of activation of the fifth component of complement by amorphous silicas. Toxicol Appl Pharmacol (2005) 0.81
alpha-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. Apoptosis (2010) 0.81
Maternal dietary loads of α-tocopherol depress protein kinase C signaling and synaptic plasticity in rat postnatal developing hippocampus and promote permanent deficits in adult offspring. J Nutr Biochem (2010) 0.81
Expression of human myoglobin in H9c2 cells enhances toxicity to added hydrogen peroxide. Biochem Biophys Res Commun (2006) 0.80
Cancer cells with high expression of CD133 exert FLIP upregulation and resistance to TRAIL-induced apoptosis. Biofactors (2008) 0.80
Identification and characterization of cancer stem cells from head and neck squamous cell carcinoma cell lines. Cell Physiol Biochem (2015) 0.80
Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to α-tocopheryl succinate. Apoptosis (2013) 0.80
Cyclopentenone prostaglandins induce endothelial cell apoptosis independent of the peroxisome proliferator-activated receptor-gamma. Eur J Immunol (2004) 0.80
Alpha-tocopheryl succinate alters cell cycle distribution sensitising human osteosarcoma cells to methotrexate-induced apoptosis. Cancer Lett (2006) 0.80
Alpha-tocopheryl succinate induces cytostasis and apoptosis in osteosarcoma cells: the role of E2F1. Biochem Biophys Res Commun (2005) 0.79
The potential role of CD133 in immune surveillance and apoptosis: a mitochondrial connection? Antioxid Redox Signal (2011) 0.79
[Role of waist circumference in the diagnosis of metabolic syndrome and assessment of cardiovascular risk in shift workers]. Med Lav (2008) 0.79
Bioinformatic analyses to select phenotype affecting polymorphisms in HTR2C gene. Hum Psychopharmacol (2011) 0.79
alpha-Lipoic acid modulates extracellular matrix and angiogenesis gene expression in non-healing wounds treated with hyperbaric oxygen therapy. Mol Med (2008) 0.78